BreakingPipeline

Cendakimab PDUFA preview: IL-13 inhibitor for eosinophilic esophagitis

Preview of the June 8, 2026 FDA decision on cendakimab for eosinophilic esophagitis: phase 3 NEJM Evidence data, Dupixent competition, PA implications, and access outlook.

PHOTO ILLUSTRATION · PHARMADOSSIER

By Ran Chen·Updated June 3, 2026·9 min read

Latest in biopharma

GLP-1 insurance coverage 2026: major payer guide

By Ran Chen#GLP-1 #Payer Coverage #Prior Authorization

Pipeline· June 3, 2026 · 10 min read

NASP PDUFA preview: anti-drug antibody strategy for uncontrolled gout

By Ran Chen#PDUFA Date #FDA Approval #Clinical Evidence

Pipeline· June 2, 2026 · 10 min read

Orca-T allogeneic cell therapy PDUFA preview: access implications for AML, ALL, and MDS

By Ran Chen#PDUFA Date #FDA Approval #Hematology

Approvals· June 2, 2026 · 9 min read

Xocova (ensitrelvir) access guide: first oral COVID post-exposure prophylaxis

By Ran Chen#FDA Approval #Infectious Disease #Specialty Drugs

Approvals· June 2, 2026 · 9 min read

Zaynich (cefepime/zidebactam) access guide: novel AMR antibiotic for resistant cUTI

By Ran Chen#FDA Approval #Infectious Disease #Specialty Drugs

Pipeline· June 1, 2026 · 10 min read

Enhertu early-stage breast cancer: neoadjuvant and adjuvant PA workflow

By Ran Chen#Oncology #FDA Approval #Prior Authorization

Biosimilars· June 1, 2026 · 12 min read

FDA biosimilar interchangeability without switching studies: the 2026 pathway

By Ran Chen#Biosimilars #Interchangeability #FDA Approval

The PharmaDossier Daily

The eight-minute biopharma briefing for access, regulatory, and commercial teams.

Launch signals, payer moves, biosimilar reads, and FDA source links every weekday.

Browse topics

Sections

Topic watch

Coverage Access100 Prior Authorization92 Payer Policy89 Formulary Strategy46 Patient Assistance44 FDA Approval34 Biosimilars30 Specialty Drugs30 Oncology27 Specialty Pharmacy27 Market Access25 Medicare Part D23 GLP-122 Clinical Evidence21

Editorial standard

Every article links back to FDA, CMS, DailyMed, Purple Book, Orange Book, ClinicalTrials.gov, or another primary source wherever the claim depends on regulated status.

Lead editor: Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.